Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer

被引：7

作者：

Martinez-Fernandez, M. I. ^{[1
,2
]}

Perez Gracia, J. L. ^{[1
,2
]}

Gil-Bazo, I. ^{[1
,2
]}

Martinez-Monge, R. ^{[1
,2
]}

机构：

[1] Univ Navarra, Dept Oncol, Clin Univ Navarra, Ave Pio 12 S-N, Pamplona, Navarre, Spain

[2] Inst Invest Biomed Navarra IDISNA, Pamplona, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2016年 / 18卷 / 07期

关键词：

SBRT; Androgen deprivation therapy; Castration resistance; MITOXANTRONE PLUS PREDNISONE; DOCETAXEL; ENZALUTAMIDE; RADIOTHERAPY; SURVIVAL;

D O I：

10.1007/s12094-015-1414-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To investigate whether bon e metastases-directed stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer (OPC). OPC is usually managed with androgen deprivation therapy (ADT). Migration to castration-resistant prostate cancer will inevitably occur in the majority of these patients. There are several strategies aimed to delay the emergence of castration resistance including intermittent ADT, second generation antiandrogens (abiraterone, enzalutamide) or metastases-directed SBRT. The present report describes two cases of patients with OPC that received SBRT 24 Gy/3Rx to the solitary bony lesion after ADT failure. Both cases showed complete and durable biochemical response for 13 and 17 months, respectively. SBRT can be used to delay the emergence of castration resistance and the need for systemic therapy when used after ADT failure.

引用

页码：743 / 747

页数：5

共 17 条

[1] Adaptation and clonal selection models of castration-resistant prostate cancer: Current perspective [J].

Ahmed, Muhammed ;

Li, Long-Cheng .

INTERNATIONAL JOURNAL OF UROLOGY, 2013, 20 (04) :362-371

[2] Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases [J].

Alongi, Filippo ;

Arcangeli, Stefano ;

Filippi, Andrea Riccardo ;

Ricardi, Umberto ;

Scorsetti, Marta .

ONCOLOGIST, 2012, 17 (08) :1100-1107

[3]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[4] Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy [J].

Berkovic, Patrick ;

De Meerleer, Gert ;

Delrue, Louke ;

Lambert, Bieke ;

Fonteyne, Valerie ;

Lumen, Nicolaas ;

Decaestecker, Karel ;

Villeirs, Geert ;

Vuye, Philippe ;

Ost, Piet .

CLINICAL GENITOURINARY CANCER, 2013, 11 (01) :27-32

[5] Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study [J].

Berthold, Dominik R. ;

Pond, Gregory R. ;

Soban, Freidele ;

de Wit, Ronald ;

Eisenberger, Mario ;

Tannock, Ian F. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :242-245

[6] Extracranial Oligometastases: A Subset of Metastases Curable With Stereotactic Radiotherapy [J].

Corbin, Kimberly S. ;

Hellman, Samuel ;

Weichselbaum, Ralph R. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) :1384-1390

[7] Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial [J].

Decaestecker, Karel ;

De Meerleer, Gert ;

Ameye, Filip ;

Fonteyne, Valerie ;

Lambert, Bieke ;

Joniau, Steven ;

Delrue, Louke ;

Billiet, Ignace ;

Duthoy, Wim ;

Junius, Sarah ;

Huysse, Wouter ;

Lumen, Nicolaas ;

Ost, Piet .

BMC CANCER, 2014, 14

[8] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. [J].

Kantoff, Philip W. ;

Higano, Celestia S. ;

Shore, Neal D. ;

Berger, E. Roy ;

Small, Eric J. ;

Penson, David F. ;

Redfern, Charles H. ;

Ferrari, Anna C. ;

Dreicer, Robert ;

Sims, Robert B. ;

Xu, Yi ;

Frohlich, Mark W. ;

Schellhammer, Paul F. ;

Ahmed, T. ;

Amin, A. ;

Arseneau, J. ;

Barth, N. ;

Bernstein, G. ;

Bracken, B. ;

Burch, P. ;

Caggiano, V. ;

Chin, J. ;

Chodak, G. ;

Chu, F. ;

Corman, J. ;

Curti, B. ;

Dawson, N. ;

Deeken, J. F. ;

Dubernet, T. ;

Fishman, M. ;

Flanigan, R. ;

Gailani, F. ;

Garbo, L. ;

Gardner, T. ;

Gelmann, E. ;

George, D. ;

Godfrey, T. ;

Gomella, L. ;

Guerra, M. ;

Hall, S. ;

Hanson, J. ;

Israeli, R. ;

Jancis, E. ;

Jewett, M. A. S. ;

Kassabian, V. ;

Katz, J. ;

Klotz, L. ;

Koeneman, K. ;

Koh, H. ;

Kratzke, R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) :411-422

[9] Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer [J].

Parker, C. ;

Nilsson, S. ;

Heinrich, D. ;

Helle, S. I. ;

O'Sullivan, J. M. ;

Fossa, S. D. ;

Chodacki, A. ;

Wiechno, P. ;

Logue, J. ;

Seke, M. ;

Widmark, A. ;

Johannessen, D. C. ;

Hoskin, P. ;

Bottomley, D. ;

James, N. D. ;

Solberg, A. ;

Syndikus, I. ;

Kliment, J. ;

Wedel, S. ;

Boehmer, S. ;

Dall'Oglio, M. ;

Franzen, L. ;

Coleman, R. ;

Vogelzang, N. J. ;

O'Bryan-Tear, C. G. ;

Staudacher, K. ;

Garcia-Vargas, J. ;

Shan, M. ;

Bruland, O. S. ;

Sartor, O. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (03) :213-223

[10] Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [J].

Petrylak, DP ;

Tangen, CM ;

Hussain, MHA ;

Lara, PN,J ;

Jones, JA ;

Taplin, ME ;

Burch, PA ;

Berry, D ;

Moinpour, C ;

Kohli, M ;

Benson, MC ;

Small, EJ ;

Raghavan, D ;

Crawford, ED .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1513-1520

← 1 2 →